Ashray Gunjur

145 Studley Road
Heidelberg, VIC 3084, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 39 publications

Nivolumab and Ipilimumab in Advanced Mismatch Repair-Deficient/Microsatellite Instability-High Noncolorectal Cancers: A Nonrandomized Clinical Trial.

Nivolumab and Ipilimumab in Advanced Mismatch Repair-Deficient/Microsatellite Instability-High Noncolorectal Cancers: A Nonrandomized Clinical Trial.

Journal: JAMA oncology

Published: November 13, 2025

A Phase I and Biodistribution Study of Ifabotuzumab, a Humanized Agonistic EphA3-Targeted Antibody, in Patients with Recurrent Glioblastoma.

A Phase I and Biodistribution Study of Ifabotuzumab, a Humanized Agonistic EphA3-Targeted Antibody, in Patients with Recurrent Glioblastoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: November 04, 2025

Nivolumab and Ipilimumab Combination Treatment in Patients with Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer: Results from the Phase II MoST-CIRCUIT Trial.

Nivolumab and Ipilimumab Combination Treatment in Patients with Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer: Results from the Phase II MoST-CIRCUIT Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: October 22, 2025

Nivolumab and Ipilimumab Combination Treatment in Advanced Ovarian and Endometrial Clear Cell Cancers: A Nonrandomized Clinical Trial.

Nivolumab and Ipilimumab Combination Treatment in Advanced Ovarian and Endometrial Clear Cell Cancers: A Nonrandomized Clinical Trial.

Journal: JAMA oncology

Published: July 03, 2025

Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial.

Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: April 20, 2025

Sequential high-dose methotrexate and cytarabine administration improves outcomes in real-world patients with primary central nervous system lymphoma: A report from the Australasian Lymphoma Alliance.

Sequential high-dose methotrexate and cytarabine administration improves outcomes in real-world patients with primary central nervous system lymphoma: A report from the Australasian Lymphoma Alliance.

Journal: EJHaem

Published: May 09, 2024

The molecular cartography of malignant and benign sebaceous tumours.

The molecular cartography of malignant and benign sebaceous tumours.

Journal: Nature communications

Published: May 05, 2024

A gut microbial signature for combination immune checkpoint blockade across cancer types.

A gut microbial signature for combination immune checkpoint blockade across cancer types.

Journal: Nature medicine

Published: June 23, 2023

Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents matter?

Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents matter?

Journal: Expert review of pharmacoeconomics & outcomes research

Published: December 21, 2022

Correction to: Poor correlation between preclinical and patient efficacy data for tumor targeted monotherapies in glioblastoma: the results of a systematic review.

Correction to: Poor correlation between preclinical and patient efficacy data for tumor targeted monotherapies in glioblastoma: the results of a systematic review.

Journal: Journal of neuro-oncology

Published: August 22, 2022

Poor correlation between preclinical and patient efficacy data for tumor targeted monotherapies in glioblastoma: the results of a systematic review.

Poor correlation between preclinical and patient efficacy data for tumor targeted monotherapies in glioblastoma: the results of a systematic review.

Journal: Journal of neuro-oncology

Published: June 02, 2022

'Know thyself' - host factors influencing cancer response to immune checkpoint inhibitors.

'Know thyself' - host factors influencing cancer response to immune checkpoint inhibitors.

Journal: The Journal of pathology

Published: February 01, 2022

Showing 1-12 of 39

Last Updated: 09/26/2026